ʻO Paxlovid kahi lāʻau noiʻi i hoʻohana ʻia no ka mālama ʻana i ka COVID-19 maʻalahi i nā pākeke a me nā keiki [12 mau makahiki a ʻoi aku ke kaupaona ʻana ma kahi o 88 paona (40 kg)] me nā hopena maikaʻi o ka hoʻāʻo viral SARS-CoV-2 pololei, a me ka poʻe i pilikia nui no ka piʻi ʻana i ka COVID-19 koʻikoʻi, me ka hoʻokipa a i ʻole ka make. He noiʻi ʻo Paxlovid no ka mea ke aʻo ʻia nei. Loaʻa ka ʻike liʻiliʻi e pili ana i ka palekana a me ka pono o ka hoʻohana ʻana iā Paxlovid e mālama i ka poʻe me COVID-19 maʻalahi.
Ua ʻae ka FDA i ka hoʻohana pilikia ʻana iā Paxlovid no ka mālama ʻana i ka COVID-19 maʻalahi i nā pākeke a me nā keiki [12 mau makahiki a ʻoi aku paha ma kahi o 88 paona (40 kg)] me kahi hōʻike maikaʻi no ka maʻi maʻi. ke kumu o COVID-19, a me ka poʻe i pilikia nui no ka piʻi ʻana i ka COVID-19 koʻikoʻi, me ka hoʻokipa a i ʻole ka make, ma lalo o kahi EUA.

ʻAʻole ʻo Paxlovid kahi lāʻau lapaʻau i ʻae ʻia e ka FDA ma United States. E kamaʻilio me kāu mea mālama ola e pili ana i kāu mau koho a inā he nīnau kāu. ʻO kāu koho e lawe iā Paxlovid.

Loaʻa iā Paxlovid nā lāʻau lapaʻau ʻelua: nirmatrelvir a me ritonavir.

ʻO Nirmatrelvir [PF-07321332] kahi mea pale protease nui (Mpro) SARS-CoV-2 (i ʻike ʻia ʻo SARS-CoV2 3CL protease inhibitor) e hana ana ma ke kāohi ʻana i ka hoʻopiʻi viral i ka wā mua o ka maʻi e pale ai i ka piʻi ʻana i ka COVID- 19.

Hoʻohana pū ʻia ʻo Ritonavir me ka nirmatrelvir e kōkua i ka hoʻolōʻihi ʻana i kāna metabolism i mea e hoʻomau ai ʻo ia i loko o ke kino no ka manawa lōʻihi ma nā pae kiʻekiʻe e kōkua i ke kaua ʻana i ka maʻi.